Thursday 16 October, 2025
Objectives: Intermittent androgen deprivation therapy (iADT) is a treatment option for selected subpopulations of prostate cancer (PCa) patients that can…
Read morePoster: Drug/Disease Modelling - Oncology
Exposure-response of different dosing schedules of naratuximab emtansine in combination with rituximab in Non Hodgkin’s lymphoma
Thursday 16 October, 2025
Objectives: Naratuximab emtansine (nara) is an antibody-drug conjugate (ADC) comprised of a humanized anti-CD37 monoclonal antibody conjugated to the cytotoxic…
Read moreDrug exposure / response model for neutropenia with lurbinectedin in cancer patients
Thursday 16 October, 2025
Objectives: Lurbinectedin is a new anticancer agent that inhibits activated transcription, induces DNA double-strand breaks generating apoptosis and modulates tumor microenvironment….
Read moreExposure–response analysis of safety and efficacy of capivasertib administered as monotherapy or in combination with fulvestrant
Thursday 16 October, 2025
Objectives: The PI3K/AKT/PTEN signalling pathway is dysregulated in various cancers. Capivasertib is a potent, selective inhibitor of all three AKT…
Read morePopulation Pharmacokinetics of Capivasertib, a Potent Selective AKT Inhibitor, in Patients with Solid Tumours
Thursday 16 October, 2025
Introduction/Objectives: The PI3K/AKT/PTEN signalling pathway has crucial roles in cell growth and survival and is associated with various cancers. Capivasertib…
Read moreComparison of tumor dynamics models and tumor growth inhibition metrics in support of decisions in early Phase Ib/II clinical oncology studies
Thursday 16 October, 2025
Introduction/Objectives: Model-derived Tumor Growth Inhibition (TGI) metrics derived may serve as predictors of overall survival (OS). However, challenges persist in…
Read moreDose-exposure-response model between an ATR inhibitor and peripheral monocytes
Thursday 16 October, 2025
Introduction: AZD6738 is a potent, selective inhibitor of the ATR protein kinase, currently being tested in patients with solid malignancies….
Read moreImportance of Quantifying Neutropenia Risk Factors in Phase I Solid Malignancy Dose Finding; A Simulation Case
Thursday 16 October, 2025
Background In Oncology drug development, the primary objective of most phase I clinical dose finding studies continues to be identification…
Read moreExposure-Response Analysis of Tovorafenib (DAY101) Relating Objective Response to Exposure, Patient- and Disease Characteristics
Thursday 16 October, 2025
Introduction: Tovorafenib (DAY101) is an oral, highly selective, CNS-penetrant, Type II pan RAF kinase inhibitor being developed for the treatment of…
Read moreOptimising Phase 1 oncology dosing schedule of an ATR inhibitor in real time using a model informed approach to predict myelosuppression
Thursday 16 October, 2025
Introduction: AZD6738 is an ATR kinase inhibitor being tested in patients with solid malignancies as monotherapy and in combination. A…
Read more